November 29, 2010

New Product Release

Regulatory

Genovis will launch two new products, FragIT™ MicroSpin and deGlycIT™ MicroSpin  during the European Antibody Engineering Congress 2010 in Geneva. Both products has been developed from Genovis’ unique enzyme techniques and target pharma-, biotechnology- and diagnostic companies that develop antibody based drugs and analysis.

Read more at:

http://www.genovis.com/fragit_microspin

http://www.genovis.com/deglycit_microspin

The Product Release is attached and published at Genovis web site: www.genovis.com

Find out more, contact: Sarah Fredriksson, CEO, Genovis AB Tel: +46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company’s patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission is our certified adviser.

wkr0005.pdf
  • Svenska